Saturday, October 31, 2026

US Awards Contract for 300-Ton Rare Earth Facility as China Controls 70% of Global Processing

The Defense Logistics Agency contracted a modular facility to produce 300 tons annually of samarium and gadolinium metals domestically. The move addresses China's control of over 70% of global rare earth processing, which creates supply vulnerabilities for defense manufacturing across allied nations facing similar dependencies.

LM Salvado
LM Salvado

March 18, 2026

US Awards Contract for 300-Ton Rare Earth Facility as China Controls 70% of Global Processing
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Defense Logistics Agency awarded a contract for metallothermal production of samarium and gadolinium metals, targeting domestic output of 300 tons per year through a modular facility design.1 China controls more than 70% of global rare earth processing, creating dependencies that threaten defense stockpiles across Western militaries during geopolitical tensions.1

The supply concentration mirrors vulnerabilities facing Japan, South Korea, and European defense industries. All rely heavily on Chinese rare earth processing despite domestic or allied mining operations in Australia, Canada, and the US. Samarium and gadolinium are critical for precision-guided munitions, radar systems, and advanced military electronics used by NATO forces.

Lead times for rare earth materials already extend 12-18 months in global commercial markets. Any disruption—whether from trade restrictions, export controls, or processing bottlenecks—cascades through international procurement chains. China previously restricted rare earth exports to Japan in 2010 during a territorial dispute, demonstrating the geopolitical leverage these materials provide.

The facility's modular design allows rapid scaling if supply conditions deteriorate. Current US rare earth mining exists, but processing capacity remains concentrated in China and Malaysia. This creates inefficiency: mined materials ship to Asia for refinement before returning as finished metals, a pattern repeated across allied supply chains.

For multinational defense contractors, the US shift signals broader procurement changes. Companies dependent on Chinese rare earth processing may face pressure to demonstrate supply chain resilience across allied markets. Pentagon acquisition rules increasingly prioritize supply security, potentially setting precedent for European and Indo-Pacific defense ministries.

Industrial manufacturers worldwide using rare earth magnets, catalysts, or alloys face similar exposure. Automotive, renewable energy, and electronics sectors from Germany to South Korea rely on these materials. Defense prioritization by major economies could tighten global commercial availability or inflate prices during shortages.

The 300-ton capacity represents a fraction of US consumption but establishes production knowledge transferable to allied nations. Tensions over Taiwan or South China Sea access could trigger coordinated supply cutoffs affecting multiple Western economies simultaneously. Procurement teams should evaluate rare earth content in supply chains now—second-sourcing and inventory buffers require years to implement effectively.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com